Dilated Cardiomyopathy - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 54 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Dilated Cardiomyopathy - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Dilated Cardiomyopathy - Pipeline Review, H2 2014', provides an overview of the Dilated Cardiomyopathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dilated Cardiomyopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dilated Cardiomyopathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Dilated Cardiomyopathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Dilated Cardiomyopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dilated Cardiomyopathy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dilated Cardiomyopathy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dilated Cardiomyopathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Dilated Cardiomyopathy Overview 6
Therapeutics Development 7
Pipeline Products for Dilated Cardiomyopathy - Overview 7
Pipeline Products for Dilated Cardiomyopathy - Comparative Analysis 8
Dilated Cardiomyopathy - Therapeutics under Development by Companies 9
Dilated Cardiomyopathy - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Dilated Cardiomyopathy - Products under Development by Companies 12
Dilated Cardiomyopathy - Companies Involved in Therapeutics Development 13
Array BioPharma Inc. 13
Kasiak Research Pvt. Ltd. 14
Sanofi 15
Vericel Corporation 16
Zensun (Shanghai) Sci & Tech Co., Ltd. 17
Dilated Cardiomyopathy - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
ARRY-797 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
CAP-1002 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ixmyelocel-T - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Neucardin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Refacell-DCM - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecule for Dilated Cardiomyopathy - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Dilated Cardiomyopathy - Recent Pipeline Updates 38
Dilated Cardiomyopathy - Dormant Projects 46
Dilated Cardiomyopathy - Product Development Milestones 47
Featured News & Press Releases 47
Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia 47
Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack 47
Apr 19, 2013: Aastrom Biosciences Announces First Patients Treated In IxCELL-DCM Clinical Study Of Ixmyelocel-T 48
Jun 06, 2012: Aastrom Presents Preclinical Data Of Ixmyelocel-T At 18th Annual International Society For Cellular Therapy Meeting 48
May 10, 2012: Treatment With Ixmyelocel-T Shows Improvement In Outcome Of Heart Failure Patients 49
May 07, 2012: Aastrom To Present Phase IIa Trial Results Of Ixmyelocel-T In Dilated Cardiomyopathy Patients At SCAI Scientific Sessions 50
Oct 03, 2011: Aastrom Receives European Composition-Of-Matter Patent For Ixmyelocel-T 50
Sep 19, 2011: Aastrom Announces Positive 12-Month Safety And Efficacy Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy 51
Sep 14, 2011: Aastrom To Present 12-Month Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy 52
May 17, 2011: Aastrom To Present Results From Two Studies of Ixmyelocel-T At International Society For Cellular Therapy Meeting 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54

List of Tables
Number of Products under Development for Dilated Cardiomyopathy, H2 2014 7
Number of Products under Development for Dilated Cardiomyopathy - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Dilated Cardiomyopathy - Pipeline by Array BioPharma Inc., H2 2014 13
Dilated Cardiomyopathy - Pipeline by Kasiak Research Pvt. Ltd., H2 2014 14
Dilated Cardiomyopathy - Pipeline by Sanofi, H2 2014 15
Dilated Cardiomyopathy - Pipeline by Vericel Corporation, H2 2014 16
Dilated Cardiomyopathy - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2014 17
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Stage and Target, H2 2014 20
Number of Products by Stage and Mechanism of Action, H2 2014 22
Number of Products by Stage and Route of Administration, H2 2014 24
Number of Products by Stage and Molecule Type, H2 2014 26
Dilated Cardiomyopathy Therapeutics - Recent Pipeline Updates, H2 2014 38
Dilated Cardiomyopathy - Dormant Projects, H2 2014 46